Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up

Clinigen reiterates guidance for 2021 revenue as virus impact continues

Thu, 26th Nov 2020

Pharmaceutical company Clinigen reiterated its outlook for 2021 organic net revenue growth to be toward the lower end of its 5%-to-10% medium-term guidance range. The company said trading in 2021 had been in-line with market expectations despite the ongoing impact of COVID-19. 'As previously stated, we expect growth to be more weighted to H2 than in previous years due to the impact of COVID-19 and the timing of shipments for Proleukin to key customers,' the company said. At 10:04am: (LON:CLIN) Clinigen Group PLC share price was 0p at 683p Story provided by

FTSE 100 Latest